

1 <http://dx.doi.org/10.1111/vco.12173>

2 **Clinical and computed tomography tumour dimension assessments for**
3 **planning wide excision of injection site sarcomas in cats: how strong is**
4 **the agreement?**

5

6 R. Ferrari¹, M. Di Giancamillo¹, D. Stefanello¹, C. Giudice¹, V. Grieco¹, M. Longo¹, G. Ravasio¹ and
7 P. Boracchi²

8 ¹Department of Veterinary Science and Public Health, Facoltà di Medicina Veterinaria, Università
9 degli Studi di Milano, Milano, Italy

10 ²Department of Clinical Science and Community, Section of Medical Statistics and Biometry,
11 Facoltà di Medicina e Chirurgia, Università degli Studi di Milano, Milano, Italy

12

13

14 **Abstract**

15 In injection site sarcoma (ISS) in cats lateral as well as deep margins should be correctly planned for
16 a successful surgical outcome. The discrepancy between clinical and computed tomography (CT)
17 measurements of dimension in resectable tumour has led to possible bias that affects the
18 subsequent surgical dose. The aim of this study was to prospectively investigate the agreement
19 between clinical and CT measurements of dimension in newly diagnosed ISS in cats. Fifty-three
20 client-owned cats that underwent both clinical and CT measurements of the length and width of ISS
21 were included. CT measurements showed a tendency towards being larger than clinical dimensions,
22 and this difference increased with increasing tumour size. Based on our results, in further studies
23 focusing on ISS in cats, the kind of assessment used to define tumour dimensions (CT versus clinic)
24 should be declared and specified to properly consider surgical results and prognostic impact of this
25 variable.

26

27 **Introduction**

28 Injection site sarcoma (ISS) in cats is a well- recognized soft tissue sarcoma characterized by very
29 aggressive local behaviour with a high probability of local recurrence and a relatively low probability
30 of distant dissemination.^{1 – 7} Although multimodal therapeutic approaches have been proposed,
31 wide margins or radical surgical excision based on tumour extent remains the primary therapeutic
32 procedure.^{6 –8} Despite the peculiar presence of asymmetric and infiltrating long tumour
33 extensions departing from the main mass making the estimation of the dimensions of ISS objectively
34 difficult to achieve,^{9 –11} many studies have used clinical measurements for prognostic and surgical
35 purposes.^{4,5,7,9} The use- fulness of advanced diagnostic imaging, such as magnetic resonance
36 imaging (MRI) and/or computed tomography (CT), to plan preoperatively the surgical excision of ISS
37 has been previously dis- cussed and suggested,^{8,9,11 – 15} but it has not always been applied for
38 surgical planning.^{4,5,7,9} The avail- able veterinary literature discuss on the amount of lateral
39 margins that should be excised around ISS in cats, whereas regarding the deep margins it has been
40 suggested to consider one or (more recently) two not infiltrated underlying muscles layers.^{6,7,9} In
41 those studies in which both clinical and advanced imaging measurements have been reported, the
42 tumour dimensions obtained with CT have generally been larger than those obtained with clinical
43 measurements.^{13,16,17} Recently differ- ent amount of lateral margins was hypothesized for
44 surgical excision of ISS in cats based on the possibil- ity that the same wide lateral margins could not
45 be equally wide if a surgeon consider the clinical or the computed tomographic measurements of
46 the same tumour.¹⁶ Size discrepancies between clinical and CT mea- surements of the same tumour
47 size can impact the surgical dose applied. The aim of the study was to prospectively investigate the
48 agreement between the clinical and CT measurements of tumour dimension in newly diagnosed ISS
49 in cats.

51 **Materials and methods**

52 Client-owned cats affected by histologically confirmed, newly diagnosed ISS18 and referred to our
53 clinic from January 2002 to December 2013 were included. Before surgery, all the cats underwent a
54 whole-body CT examination for staging of oncologic disease, and clinical and CT evaluations of
55 tumour dimensions were performed on the same date by the same clinician and the same radiologist,
56 respectively. The surgeon and the radiologist were blinded to the CT and clinical
57 measurements, respectively. All the owners provided written consent before the clinical and
58 diagnostic procedures.

59 The clinical measurements were obtained before a whole-body CT examination of the anaesthetised
60 cats. The cats were placed in sternal recumbency when the tumour was localized on the dorsal
61 thorax and dorsal abdomen or in lateral recumbency when it was localized on the lateral thorax or
62 abdomen. The clinical dimensions (CD) obtained by the surgeon were the longest length (CD-l) and
63 the longest width (CD-w) of the palpable tumour, measured with digital callipers. All the CT
64 measurements were performed with the patients in sternal recumbency with the forelimbs
65 extended cranially, even when the ISS was localized in the interscapular region, and double
66 positioning was performed with the forelimbs flexed/extended.¹¹ The dimensions obtained by CT
67 (CTDs) were measured by the radiologist (Aycan Workstation OsiriXPRO Manager, Aycan
68 Digitalsysteme GmbH, Würzburg, Germany) and consisted of the longest length (CTD-l) and the
69 longest width (CTD-w) of the tumour with a soft tissue window (Window Width 350, Window Level
70 40), based on post-contrast CT images (PQ2000S, Philips, Amsterdam, the Netherlands; single slice
71 fourth generation CT, with slice thickness of 1 – 3 mm, pitch = 1, 200 – 250 mA) after an intravenous
72 injection via the cephalic vein of non-ionic contrast medium (Iohexol 350 mgI mL⁻¹, Omnipaque GE
73 Healthcare, Milan, Italy) at a dose of 600 mg I kg⁻¹.¹⁹ For both the clinical and CT dimensions, we
74 defined 'length' as the cranio-caudal axis of the tumour and 'width' as the transversal axis for an

75 ISS located on the dorsal thorax and dorsal abdomen or as the dorsum– ventral axis for an ISS
76 located on the lateral side of the body.

77 The shape of each tumour was also considered and was categorized as ‘regular-shaped’ when the
78 tumour had a spheroidal (the two axes beings approximately equal) or oval (when one axis was
79 longer than the other) shape and ‘irregular-shaped’ when a geometric shape was not recognizable.

80 This variable was obtained both by clinical evaluation (CD-shape) and by CT imaging (CTD-shape).

81 For each cat, the following data were also recorded: breed, age, sex, weight, body condition score
82 (BCS – from 1 to 5)²⁰ and site of the tumour.

83

84 **Statistical analysis**

85 In the absence of a ‘gold standard’ method for defining the tumour size of ISS, the agreement
86 between dimensions retrieved by clinical and CT measure- ments was evaluated according to the
87 Bland and Altman approach,²¹ representing the relationship between the differences between the
88 two methods (CTD –CD) versus the average [$1/2(CTD + CD)$]. The limits of agreement were than
89 obtained as the values containing 95% of the differences between the two measurements. If, on the
90 basis of clinical consideration, the limits of agreement were considered too wide, it can be
91 concluded that the two measurements disagree, and they cannot be considered ‘interchangeable’.

92 In the simplest situation, differences and their variability do not depend on the tumour size being
93 measured, and the lack of agreement can be simply summarized by the bias (estimated by the mean
94 of the differences) and the standard deviation of the differences. In the absence of a gold standard
95 method, neither of the two measurements can be assumed to be ‘true’, and the average of the two
96 measurements is considered an estimate of the tumour size being measured. The assumption of
97 constant difference between the two measurements was evaluated by a regression model of the
98 differences as a function of the aver- ages and by assessing whether the estimated slope was equal

99 to 0. The assumption of constant variability was evaluated by a regression model of the absolute
100 value of the residuals of the above-cited regression model as a function of the averages and by
101 assessing whether the estimated slope was equal to 0.22 In the case of non-constant differences
102 and non- constant variances, the bias and approximate limits of agreement were obtained by
103 considering a linear relationship between differences and averages and between standard
104 deviations and averages.^{22,23} A measurement of overall concordance, using the concordance
105 correlation coefficient (CCC), was obtained according to Lin et al.²⁴ The value of CCC ranges
106 between -1 (perfect discordance) to 1 (perfect concordance). A value of 0 corresponds to the lack
107 of a relationship between the two measurements. The CCC is subdivided into its components:
108 precision and accuracy. The 95% confidence interval (95% CI) of the CCC was obtained by the boot-
109 strap method. Because of the limited number of cases, only an overall analysis was performed for
110 all of the cases, and for a subsample of cases in which the tumours were retained as 'regular-shaped'
111 by both measurement methods, without considering other clinical characteristics of the subjects.
112 The 95% CI for the proportions of the disagreement between the classification of the tumour shape
113 as regular-shaped or irregular-shaped on the basis of clinical and CT evaluations was obtained by
114 the 'exact method' procedure suggested by Clopper and Pearson.²⁵
115 To evaluate the risk of failure in eliminating over- all tumour mass, using a safety margins of 3 and
116 5 cm starting from each side of the clinical measurement, length and width of clinical measurements
117 were firstly added by 6 and 10 cm, respectively and then the percentages of clinical measures
118 exceeding CT measurement were calculated with the corre- sponding exact 95% CI. The statistical
119 analysis was performed using the R and MethComp software packages (www.r-project.org). A P
120 value ≤ 0.05 was considered statistically significant.

121

122

123 **Results**


124 Fifty-three cats were prospectively included in the study. Forty-eight were domestic short-hair cats,
125 two were Persian, two were Norwegian forestcats, and one was a Chartreux. Thirty-two cats were
126 female (of which 31 were spayed), and 21 cats were male (of which 19 were castrated). The median
127 age at presentation was 10 years old (range:4 – 16 years). The median body weight was 4.5 kg
128 (range, 3 –8.5 kg). The body weight was not avail- able for two cats. Eight cats had a BCS of 2 of 5,
129 31hada BCS of 3 of 5,9 had a BCS of 4 of5 and5 had a BCS of 5 of 5. Thirty-one tumours were located
130 on the inter- scapular region, 13 were on the lateral thorax, 8 were on the lateral abdomen and 1
131 was on the lumbar region. Forty-eight tumours were histologically diagnosed as fibrosarcomas (2/48
132 with areas of chondroid metaplasia) and five as malignant fibrous histiocytomas. Moderate to
133 abundant inflammation was seen in all tumours. Inflammatory cells were mainly represented by
134 lymphocytes and fewer macrophages.

135 The median CD measured was 3 cm (range: 0.5 –10 cm). Both the median CD-l and median CD-
136 w were 3 cm (range: 0.5 –10 cm and 0.7 – 10 cm, respectively). The CD-shape evaluation considered
137 46 cases as regular-shaped tumours (spheroidalin 34 cases, oval in 12 cases) and seven cases as
138 irregular-shaped tumours.

139 The median CTD measured was 5 cm (range: 0.6 –13 cm). The median CTD-l was 5 cm (range:
140 0.9 –12.7 cm), and the median CTD-w was 4.4 cm (range: 0.6 – 13 cm). The CTD-shape evaluation
141 considered 41 cases as regular-shaped tumours (spheroidal in 18 cases, oval in 23 cases) and 12
142 cases as irregular-shaped tumours. Concerning the shapes of the tumours, 36 cases were classified
143 as regular-shaped, and 3 tumours were classified as irregular-shaped by both measurement
144 methods. Five of 53 cases (9.4%; 95% CI: 3.13 –20.66%) were classified as irregular-shaped according
145 to clinical measurements and as regular-shaped according to CT measurements, whereas 9 of 53

146 cases (17%; 95% CI: 8.07 – 29.80%) were classified as regular-shaped according to clinical
147 measurements and as irregular-shaped according to CT measurements.

148



149

150 *Figure 1. (A) Tumour length on the whole tumour series: clinical measure against*
151 *tomography measure. The couple of measurements for each tumour are represented by points and*
152 *the line represents the putative perfect agreement between the two measures. (B) Bland–Altman*
153 *plot describing the agreement between the computed tomography measure of tumour length and*
154 *the clinical measure of tumour length on the whole tumour series. The couple of measurements for*
155 *each tumour are represented by points. The central line is the estimated bias and lower and upper*
156 *lines are the estimated limits of agreement. (C) Bland–Altman plot describing the agreement*
157 *between the computed tomography measure of tumour length and the clinical measure of tumour*
158 *length on the subsample of regular-shaped tumours. The couple of measurements for each tumour*
159 *are represented by points. The central line is the estimated bias and lower and upper lines are the*
160 *estimated limits of agreement.*

161

162

163

164 **Length**

165 The relationships between the CT and clinical measurements are reported in Figure 1A. In the
166 majority of tumours, the CT measurement was larger than the clinical measurement (Figure 1B).

167 A plot of the differences between the two measurements (CTD – CD) against their averages
168 suggested a tendency of the differences to increase with increasing of the estimated tumour length
169 (slope of the estimated regression coefficient is 0.1403, P = 0.27) and a tendency of the variability
170 of the differences to increase with increasing of the estimated tumour length (slope of the
171 estimated regression coefficient is 0.15194, P = 0.06). Because of the small size of the case series,
172 although the estimated regression coefficients were not significantly different from 0, a
173 conservative approach was applied, accounting for possible increases in difference and variability.

174 The corresponding estimated bias and limits of agreement are reported in Figure 1B. The estimated
175 bias ranged from 1.2 cm for an estimated tumour size of 1 – 2.18 cm for an estimated tumour size
176 of 8 cm. The estimated limits of agreement became wider with increasing estimated tumour length,
177 starting with values of bias of ± 2.24 for an estimated tumour length of 1 cm to bias of approximately
178 ± 4.9 for an estimated tumour size of 8 cm (Figure 1B). The CCC between the two measurements
179 was 0.52 (95% CI: 0.27 – 0.69) with corresponding precision of 0.66 and accuracy of 0.78. The value
180 of this CCC also suggested unsatisfactory concordance between the clinical and CT dimensions.


181 Considering the analysis of the subsample of 36 tumours classified as ‘regular-shaped’ using both
182 clinical and CT evaluations, the results were similar (Figure 1C). The estimated regression slopes for
183 the difference between measurements as a function of the estimated length and for the variability
184 of the difference as a function of estimated length were 0.20 (P = 0.12) and 0.09 (P = 0.21),
185 respectively. The estimated bias and limits of agreement started at 0.74 ± 2.44 for an estimated
186 tumour length of 1 cm and ranged to 2.14 ± 4.12 for an estimated tumour length of 8 cm (Figure
187 1C). The estimated CCC was 0.63 (95% CI: 0.36 – 0.81).

188 **Width**

189 The relationships between CT and clinical measurements of width are reported in Figure 2A. The
190 tendency of a CT measurement to be larger than the clinical measurement was less evident than
191 the observed pattern for length (Figure 2A). A plot of the difference between the two measurements
192 (CTD – CD) against their average suggested a tendency of the differences to increase with increasing
193 estimated tumour width (slope of the estimated regression coefficient was 0.1453; P = 0.32). The
194 increase in the variability of the differences with increasing estimated tumour width was evident
195 and was confirmed by the regression analysis (slope of the estimated regression coefficient was
196 0.25055; P = 0.0062). Although the estimated regression coefficients were not both significantly
197 different from 0, a conservative approach was applied, accounting for the possible increase in
198 difference and variability as a function of the estimated tumour width. The corresponding bias and
199 limits of agreement are reported in Figure 2B. The estimated bias ranged from 0.5 for an estimated
200 tumour width of 1 cm to 1.55 for an estimated tumour width of 8 cm. The limits of agreement
201 became wider with increasing estimated tumour width, ranged from values for bias of
202 approximately ± 2.1 for an estimated tumour size of 1 cm to bias of approximately ± 6.44 for an
203 estimated tumour size of 8 cm (Figure 2B). The CCC between the two measurements was 0.52 (95%
204 CI: 0.27 – 0.68) with corresponding precision of 0.57 and accuracy of 0.92. The value of this CCC also
205 suggested an unsatisfactory concordance between the clinical and CT measurements.

206 Considering the analysis of the subsample of 36 cases classified as ‘regular-shaped’ tumours using
207 both clinical and CT evaluations, the trend towards an increase in the difference between
208 measurements with the increase in estimated tumour width is very weak (slope of the estimated
209 regression coefficient was 0.05; P = 0.68), as was the trend towards an increase in the difference in
210 variability with the increase in estimated tumour width (slope of the estimated regression
211 coefficient was 0.04, P = 0.57). The average bias between the two measurements was approximately

212 0.56 cm, and the average limits of agreement were approximately -2.67 and 3.80 , respectively
 213 (Figure 2C). The estimated CCC was 0.73 (95% CI: $0.50 - 0.86$). Considering the addition of a lateral
 214 margins to each side of the clinical measurement, only in two cases CTD-I was greater than CD-I
 215 added by 6 cm (3.78%: 95% confidence interval $0.46 - 12.98\%$) and only in one case CTD-w was
 216 greater than CD-w added by 6 cm (1.89%: 95% confidence interval $0.048 - 10.07\%$). Overall, if 3 cm
 217 for each side are added to CD, the risk of failure to eliminate the corresponded tumour highlights
 218 by CT should be $3/53$ (5.7%, 95% confidence interval $1.18 - 15.66\%$). If 5 cm for each side were added
 219 to CD, no CTD was greater than CD added by 10 cm. The risk was estimated to be $0/53 = 0\%$,
 220 nevertheless, after computing 95% CI, the upper limit was 6.72%.



221
 222 *Figure 2. (A) Tumour width on the whole tumour series: clinical measure against computed*
 223 *tomography measure. The couple of measurements for each tumour are represented by points and*
 224 *the line represents the putative perfect agreement between the two measures. (B) Bland–Altman*
 225 *plot describing the agreement between the computed tomography measure of tumour width and*

226 *the clinical measure of tumour width on the whole tumour series. The couple of measurements for*
227 *each tumour are represented by points. The central line is the estimated bias and lower and upper*
228 *lines are the estimated limits of agreement. (C) Bland–Altman plot describing the agreement*
229 *between the computed tomography measure of tumour width and the clinical measure of tumour*
230 *width on the subsample of regular-shaped tumours. The couple of measurements for each tumour*
231 *are represented by points. The central line is the estimated bias and lower and upper lines are the*
232 *estimated limits of agreement.*
233

234 **Discussion**

235 Tumour dimension is one of the first aspects evaluated in the pre-operative setting, to outline the
236 prognostic consultation, as well as to calibrate the surgical dose. These considerations are
237 particularly relevant for ISS in cats because the correct surgical approach is crucial for ensuring clean
238 surgical margins and increasing the probability of a cure.^{6,10,15} In addition, the dimensions of ISS
239 in cats influence the surgical time and therefore indirectly impacted the risk of wound healing
240 complications, which could induce postoperative morbidity and postpone other adjuvant
241 therapies.¹⁶ Despite the relevance of such aspects, a standardized approach for measuring the
242 dimensions of ISS in cats is not currently available. In small animal oncology, especially when dealing
243 with feline ISS, the use of advanced imaging techniques in the pre-surgical setting has recently
244 increased, but their use is still not a rule, and it is mostly left to surgeon choice.^{4,7,9,15,16}
245 In this study, tumour dimensions, both length and width, evaluated by CT showed a tendency
246 towards being larger than the dimensions measured with calipers, consistent with previous
247 reports.^{13,16,17} In addition, in a proportion of cats, the shapes retrieved by the two methods
248 demonstrated discrepancies. These findings could be related to the specific characteristics of ISS
249 and specifically to the presence of non-palpable tumour extensions departing from the clinically
250 palpable tumour. These thin tumour peripheral projections are mostly detectable only with CT
251 contrast medium or histologically.^{10,11,17} Actually, these extensions are not always composed of
252 neoplastic cells because inflammatory infiltration (small lymphocytes and rarer macrophages) and
253 the rich neovascularization that often histologically characterizes ISS can also be highlighted by CT

254 contrast medium.^{11,12,18} A distinction between neoplastic and inflammatory tissue can be
255 achieved only histologically; however, it has been suggested that inflammatory tissue around an ISS
256 should also be excised.¹¹ Therefore, the tumour burden in this study included all the tissue
257 enhanced by the CT contrast medium. The difference between tumour dimensions obtained with
258 the two techniques was also corroborated by the statistical analysis, which revealed a weak
259 concordance between clinical and CT evaluations of tumour dimensions. This weak concordance
260 was confirmed even when considering the subsample of 'regular-shaped' tumours, in which greater
261 agreement was expected. Moreover, other results also showed wide limits of agreement,
262 particularly with increasing tumour size, indicating that, when the surgeon clinically measures the
263 tumour, a wide range of possible CT measurements is possible. In addition, this range of possible
264 values became wider if the tumour increased in size. This could be explain by the hypothesis that a
265 tumour that has the ability and/or the time to grow also has a greater likelihood of infiltrating the
266 surrounding tissues, forming longer tumour extensions and thus increasing the discrepancy
267 between the two methods of measurement by increasing the tumour dimensions. Another
268 explanation could be that, while CT images allow for the precise evaluation of only the tumour
269 edges, when the tumour was clinically measured with calipers, the thickness of the skin and soft
270 tissues that covered the mass could not be subtracted from the value obtained, and other variables
271 related to the single cat, such as BCS and the anatomical site of the tumour, could contribute to that
272 variability. These findings suggested that it is not correct to estimate the tumour size only using one
273 method of assessment but rather than both methods should be applied.

274 The gold standard for measuring tumour dimensions should be the method that provides a value
275 closer to the real dimensions of the tumour. In human breast cancer, another tumour category in
276 which surgery is the mainstay of treatment, the gold standard is to obtain the tumour size measured
277 by pathology, and with calibration, it is possible to record which technique of measurement

278 applicable in the pre-surgery setting was closer to that gold standard.²⁶ Unfortunately, in the
279 specific case of ISS in cats, the gold standard method for tumour measurement remains unknown.
280 Some studies have emphasized the utility of advanced imaging techniques for better clarifying
281 tumour edges and planning excision,^{8,9,11 – 15} but the real impact of this procedure on surgical
282 and oncologic outcomes, rather than being applied for clinical evaluation only, has not been well
283 documented.⁸ In the absence of a gold standard, it is not possible to determine the perfect pre-
284 surgical approach. The wide margins proposed for ISS excision have ranged from 3 to 5 cm,^{6,8} as
285 previously hypothesized,¹⁶ the results of the study emphasized the necessity for the surgeon to
286 approach the same ISS in a different manner, depending on whether the tumour dimensions were
287 obtained with CT or calipers. In cases of clinical measurement the widest margin should be required,
288 whereas in cases of tumour dimensions obtained with CT this margin could be reduced. Recently, in
289 fact, a wider margin of excision of 5 cm of healthy tissue around clinically palpable margins of ISS in
290 cats that did not undergo a pre-surgical CT examination was proposed.⁷ In the case series of this
291 study the addition of 10 cm (5 cm of margins for each side of the linear measurement) to the value
292 obtained clinically led to include all the measures retrieved by CT. Simplistically this result seemed
293 to suggest that using a safety margin of 5 cm around palpable mass almost all tumour detectable
294 tomographically would be excised. At the same time it is also probable that for some of these
295 tumours a 5 cm margins in clinics correspond to a marginal excision of the tumour highlighted by
296 the CT contrast-medium. Based on this consideration, a perspective randomized study comparing
297 the two methods of size assessment (and consequent margin of excision) in relation to onco- logical
298 outcome should be deal in further studies.

299 The dimensions of the tumours in cats are often reported as maximum diameters,^{7,9,15} but in this
300 study, two perpendicular axes were considered because the major axis between length and width
301 on clinical evaluation is not necessarily the major axis even on CT evaluation, thus making the

302 comparison between the two methods susceptible to bias. The third axis was not calculated because
303 of presence of anatomical limits, such as underlying bone or cavities, making it impossible to mea-
304 sure clinically with calipers the thickness of the tumour. These data are therefore not available for
305 comparison with CT measurements. In addition, the surgeon calibrates the depth of the excision
306 based on the infiltration of fascial planes and not based on linear measurement of the thickness.
307 Regarding this practice, the use of CT evaluation could facilitate the identification of deep soft and
308 bone tissue infiltration,^{11,15} the detection of which is not always easy to perform in a clinical
309 fashion. The use of other measurements, e.g. area, was not applied because these data could only
310 be retrieved using a mathematical formula that approximates the real extension of the tumour,
311 particularly in 'irregular-shaped' tumours, so a comparison of linear measurements was considered
312 more appropriate.

313 This study emphasized that dimension of a ISS in cats obtained with CT are often larger than those
314 measured with calipers. This finding suggested that the margin of excision in cases of clinical
315 measurements should be larger than in cases of CT evaluation. These difference highlighted the
316 necessity to declare and standardize the method of tumour dimension assessment in studies
317 focusing on ISS in cats in order to properly consider surgical results and prognostic impact of this
318 variable. As it has already been reported in the literature, the useful- ness of contrast-enhanced
319 whole-body CT for ISS in cats is not only linked to the role of planning lateral excision margins, but
320 it also has the ability to estimate deep margins and to detect distant metastasis.^{11,27} These aspects
321 are crucial points to discuss before surgery with surgical staff and the owner. Further studies are
322 necessary to evaluate other advanced imaging techniques, such as MRI, and to introduce a gold
323 standard method to create guidelines for the pre-surgical evaluation of the dimension of ISS in cats.

324

325 **Conflict of interest**

326 None of the authors has any financial or personal relationships that could inappropriately influence
327 or bias the content of this paper.

328

329 **References**

330 1. Hershey AE, Sorenmo KU, Hendrick MJ, Shofer FS and Vail DM. Prognosis for premused
331 feline vaccine-associated sarcoma after excision: 61 cases (1986 –1996). Journal of the American
332 Veterinary Medical Association 2000; 216: 58 – 61.

333 2. Bregazzi VS, LaRue SM, McNeil E, Macy DW, Dernell WS, Powers BE, et al. Treatment with a
334 combination of doxorubicin, surgery, and radiation versus surgery and radiation alone for cats
335 with vaccine-associated sarcomas: 25 cases (1995 –2000). Journal of the American Veterinary
336 Medical Association 2001; 218: 547 –550.

337 3. Cohen M, Wright JC, Brawner WR, Smith AN, Henderson R and Behrend EN. Use of surgery
338 and electron beam chemotherapy, for treatment of vaccine-associated sarcomas in cats: 78 cases
339 (1996 –2000). Journal of the American Veterinary Medical Association 2001; 219: 1582 –1589.

340 4. Martano M, Morello E, Ughetto M, Iussich S, Petterino C, Cascio P, et al. Surgery alone
341 versus

342

343 surgery and doxorubicin for the treatment of feline injection-site sarcomas: a report in 69 cases.
344 The Veterinary Journal 2005; 170: 84 – 90.

345 5. Dillon CJ, Mauldin N and Baer KE. Outcome following surgical removal of nonvisceral soft
346 tissue sarcomas in cats: 42 cases (1992 –2000). Journal of the American Veterinary Medical
347 Association 2005; 227: 1955 –1957.

348 6. Martano M, Morello E and Buracco P. Feline injection-site sarcoma: past, present and
349 future perspectives. The Veterinary Journal 2011; 188: 136 – 141.

- 350 7. Phelps HA, Kuntz CA, Milner RJ, Powers BE and Bacon NJ. Radical excision with five-
351 centimeter margins for treatment of feline injection-site sarcomas: 91 cases (1998 –2002). Journal
352 of the American Veterinary Medical Association 2011; 239: 97 – 106.
- 353 8. Ladlow J. Injection site-associated sarcoma in the cat: treatment recommendations and
354 results to date. Journal of Feline Medicine and Surgery 2013; 15:
355 409 – 418.
- 356 9. Romanelli G, Marconato L, Olivero D, Massari F and Zini E. Analysis of prognostic factors
357 associated with injection-site sarcomas in cats: 57 cases
358 (2001 –2007). Journal of the American Veterinary Medical Association 2008; 232: 1193 –1199.
- 359 10. Giudice C, Stefanello D, Sala M, Cantatore M, Russo F, Romussi S, et al. Feline injection-site
360 sarcoma: recurrence, tumour grading and surgical margin status evaluated using the three-
361 dimensional histological technique. The Veterinary Journal 2010; 186: 84 – 88.
- 362 11. Travetti O, Di Giancamillo M, Stefanello D, Ferrari R, Giudice C, Grieco V, et al. Computed
363 tomography characteristics of fibrosarcoma – a histological subtype of feline injection-site
364 sarcoma. Journal of Feline Medicine and Surgery 2013; 15: 488 – 493.
- 365 12. Morrison WB and Starr RM. Vaccine-associated Feline Sarcoma Task Force. Vaccine-
366 associated feline sarcomas. Journal of the American Veterinary Medical Association 2001; 218:
367 697 –702.
- 368 13. McEntee MC and Page RL. Feline
369 vaccine-associated sarcoma. Journal of Veterinary Internal Medicine 2001; 15: 176 –182.
- 370 14. Rousset N, Holmes MA, Caine A, Dobson J and Herrtage ME. Clinical and low-field MRI
371 characteristics of injection site sarcoma in 19 cats. Veterinary Radiology & Ultrasound 2013; 54:
372 623 – 629.

- 373 15. Bray J and Polton G. Neoadjuvant and adjuvant chemotherapy combined with anatomical
374 resection
375
376 of feline injection-site sarcoma: results in 21 cats. *Veterinary and Comparative Oncology* 2014.
377 doi:10.1111vco.12083..
- 378 16. Cantatore M, Ferrari R, Boracchi P, Gobbetti M, Travetti O, Ravasio G, et al. Factors
379 influencing wound healing complications after wide excision of injection site sarcomas of the trunk
380 of cats. *Veterinary Surgery* 2014; 43: 783 –790.
- 381 17. Amory JT, Jones JC, Binder EM, LeRoith T, Reasor KP, Johnson KA, et al. What is your
382 diagnosis? Injection site sarcoma. *Journal of the American Veterinary Medical Association* 2010;
383 237: 155 –156.
- 384 18. Couto SS, Griffey SM, Duarte PC and Madewell BR. Feline vaccine-associated fibrosarcoma:
385 morphologic distinctions. *Veterinary Pathology* 2002; 39: 33 – 41.
- 386 19. Pollard R and Puchalski S. CT contrast media and applications. In: *Veterinary Computed*
387 *Tomography*. 1st edn., Oxford, Wiley-Blackwell, 2011: 47 – 65.
- 388 20. Lund EM, Amstrong PJ, Kirk CA, Kolar LM and Klausner JS. Health status and population
389 characteristics of dogs and cats examined at private veterinary practices in the United States.
390 *Journal of the American Veterinary Medical Association* 1999; 214: 1336 –1341.
- 391 21. Bland JM and Altman DG. Statistical methods for assessing agreement between two
392 methods of clinical measurement. *Lancet* 1986; 327: 307 –310.
- 393 22. Bland JM and Altman DG. Measuring agreement in method comparison studies. *Statistical*
394 *Methods in Medical Research* 1999; 8: 135 – 160.

- 395 23. Carstensen B. Two methods with a single measurement on each. In: Comparing Clinical
396 Measurement Methods: A Practical Guide. 1st edn., Chichester, John Wiley & Sons Ltd, 2010: 21 –
397 47.
- 398 24. Lin L, Hedayat AS, Sinha B and Yang M. Statistical methods in assessing agreement: models,
399 issues, and tools. *Journal of American Statistical Association* 2002; 97: 257 – 270.
- 400 25. Clopper CJ and Pearson ES. The use of confidence or fiducial limits illustrated in the case of
401 the binomial. *Biometrika* 1934; 26: 404 –413.
- 402 26. Marinovich ML, Macaskill P, Irwig L, Sardanelli F, von Minckwitz G, Mannounas E, et al.
403 Meta-analysis of agreement between MRI and pathologic breast tumour size after neoadjuvant
404 chemotherapy. *British Journal of Cancer* 2013; 109: 1528 –1536.
- 405 27. Vignoli M, Terragni R, Rossi F, Frühauf L, Bacci B, Ressel L, et al. Whole computed
406 tomographic characteristics of skeletal and cardiac muscular metastatic neoplasia in dogs and cats.
407 *Veterinary Radiology & Ultrasound* 2013; 54: 223 – 230.